Tags

Type your tag names separated by a space and hit enter

A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.
Neuropsychopharmacology. 2012 Jun; 37(7):1689-98.N

Abstract

There are no FDA-approved pharmacotherapies for cannabis dependence. Cannabis is the most widely used illicit drug in the world, and patients seeking treatment for primary cannabis dependence represent 25% of all substance use admissions. We conducted a phase IIa proof-of-concept pilot study to examine the safety and efficacy of a calcium channel/GABA modulating drug, gabapentin, for the treatment of cannabis dependence. A 12-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 50 unpaid treatment-seeking male and female outpatients, aged 18-65 years, diagnosed with current cannabis dependence. Subjects received either gabapentin (1200 mg/day) or matched placebo. Manual-guided, abstinence-oriented individual counseling was provided weekly to all participants. Cannabis use was measured by weekly urine toxicology and by self-report using the Timeline Followback Interview. Cannabis withdrawal symptoms were assessed using the Marijuana Withdrawal Checklist. Executive function was measured using subtests from the Delis-Kaplan Executive Function System. Relative to placebo, gabapentin significantly reduced cannabis use as measured both by urine toxicology (p=0.001) and by the Timeline Followback Interview (p=0.004), and significantly decreased withdrawal symptoms as measured by the Marijuana Withdrawal Checklist (p<0.001). Gabapentin was also associated with significantly greater improvement in overall performance on tests of executive function (p=0.029). This POC pilot study provides preliminary support for the safety and efficacy of gabapentin for treatment of cannabis dependence that merits further study, and provides an alternative conceptual framework for treatment of addiction aimed at restoring homeostasis in brain stress systems that are dysregulated in drug dependence and withdrawal.

Authors+Show Affiliations

The Scripps Research Institute, Pearson Center for Alcoholism and Addiction Research, La Jolla, CA 92037, USA. mason@scripps.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

22373942

Citation

Mason, Barbara J., et al. "A Proof-of-concept Randomized Controlled Study of Gabapentin: Effects On Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-dependent Adults." Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, vol. 37, no. 7, 2012, pp. 1689-98.
Mason BJ, Crean R, Goodell V, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689-98.
Mason, B. J., Crean, R., Goodell, V., Light, J. M., Quello, S., Shadan, F., Buffkins, K., Kyle, M., Adusumalli, M., Begovic, A., & Rao, S. (2012). A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 37(7), 1689-98. https://doi.org/10.1038/npp.2012.14
Mason BJ, et al. A Proof-of-concept Randomized Controlled Study of Gabapentin: Effects On Cannabis Use, Withdrawal and Executive Function Deficits in Cannabis-dependent Adults. Neuropsychopharmacology. 2012;37(7):1689-98. PubMed PMID: 22373942.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. AU - Mason,Barbara J, AU - Crean,Rebecca, AU - Goodell,Vivian, AU - Light,John M, AU - Quello,Susan, AU - Shadan,Farhad, AU - Buffkins,Kimberly, AU - Kyle,Mark, AU - Adusumalli,Murali, AU - Begovic,Adnan, AU - Rao,Santosh, Y1 - 2012/02/29/ PY - 2012/3/1/entrez PY - 2012/3/1/pubmed PY - 2012/9/22/medline SP - 1689 EP - 98 JF - Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology JO - Neuropsychopharmacology VL - 37 IS - 7 N2 - There are no FDA-approved pharmacotherapies for cannabis dependence. Cannabis is the most widely used illicit drug in the world, and patients seeking treatment for primary cannabis dependence represent 25% of all substance use admissions. We conducted a phase IIa proof-of-concept pilot study to examine the safety and efficacy of a calcium channel/GABA modulating drug, gabapentin, for the treatment of cannabis dependence. A 12-week, randomized, double-blind, placebo-controlled clinical trial was conducted in 50 unpaid treatment-seeking male and female outpatients, aged 18-65 years, diagnosed with current cannabis dependence. Subjects received either gabapentin (1200 mg/day) or matched placebo. Manual-guided, abstinence-oriented individual counseling was provided weekly to all participants. Cannabis use was measured by weekly urine toxicology and by self-report using the Timeline Followback Interview. Cannabis withdrawal symptoms were assessed using the Marijuana Withdrawal Checklist. Executive function was measured using subtests from the Delis-Kaplan Executive Function System. Relative to placebo, gabapentin significantly reduced cannabis use as measured both by urine toxicology (p=0.001) and by the Timeline Followback Interview (p=0.004), and significantly decreased withdrawal symptoms as measured by the Marijuana Withdrawal Checklist (p<0.001). Gabapentin was also associated with significantly greater improvement in overall performance on tests of executive function (p=0.029). This POC pilot study provides preliminary support for the safety and efficacy of gabapentin for treatment of cannabis dependence that merits further study, and provides an alternative conceptual framework for treatment of addiction aimed at restoring homeostasis in brain stress systems that are dysregulated in drug dependence and withdrawal. SN - 1740-634X UR - https://www.unboundmedicine.com/medline/citation/22373942/A_proof_of_concept_randomized_controlled_study_of_gabapentin:_effects_on_cannabis_use_withdrawal_and_executive_function_deficits_in_cannabis_dependent_adults_ L2 - https://doi.org/10.1038/npp.2012.14 DB - PRIME DP - Unbound Medicine ER -